BeStock  
Stocks › Biotechnology › CBIO

Crescent Biopharma CBIO

US equityMarket cap rank #3744Biotechnology
$13.49 −$0.08 (-0.59%)
Market closed · Oct 8, 7:00 am ET · Last extended-hours $13.49 0.00%
Open$13.47
Prev close$13.57
Day range$13.27 – $14.20
Volume1.05M
Market cap$501.07M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average-14.8%BearishTrading below the 20-day average of $15.84
Price vs 50-day average-19.0%BearishTrading below the 50-day average of $16.65
Price vs 200-day average-14.3%BearishTrading below the 200-day average of $15.75
50-day vs 200-day50d above 200dBullishThe 50-day average is above the 200-day average
RSI (14)31.5BearishMomentum leans negative
MACD (12,26,9)-1.07BearishMACD line is below its signal line
Bollinger band position22%BearishInside the 20-day bands

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$15.84-14.8%
50-day SMA$16.65-19.0%
200-day SMA$15.75-14.3%

Recent price levels

LevelPrice
20-day high$20.40
20-day low$13.27
60-day high$22.33
60-day low$13.27
Upper Bollinger band$20.09
Lower Bollinger band$11.59

The 50-day average is currently 5.7% above the 200-day average — consistent with a “golden cross” (bullish) configuration.

30-day volatility74.1%
Average true range8.49% of price
Max drawdown (1y)-50.0%
Volume (10d vs 90d)1.15x

Discussion

No comments yet — be the first to weigh in on CBIO.

Leave a comment

Scroll to Top